CTLA4 and neoplasm: Combination therapies involving Mg2+ modulators (e.g.: ionophores) with anti-PD-1/CTLA-4 agents could reverse the “cold” tumor phenotype, whereas Mg2+ chelators (e.g.: EDTA) might improve chemotherapy sensitivity [41].